Ann: Quarterly Cash Flow and Summary of Activities, page-42

First 42 Last

Share
Profile

Follow
TitusPullo

4,698 Posts.

72

23/10/19

15:02

Post #: 41032604
Share

Originally posted by Just_a_guy ↑

i was initially very interested in ime because of South America/developing world.
They have a clear first mover advantage in South America and as the presentation suggests, they are replacing archaic systems including wet film. This provides a great tailwind.

So why on earth are they wasting time and money on aus and America? They don’t have a hope of competing in those markets. The cost of pacs/ris for a radiology clinic is a tiny tiny fraction of revenue in developed countries, and therefore radiology providers are going to favour efficiency over cost (except sometimes in the public health sector in aus but care stream and cdn are competitors in that space too). So ime trying to undercut their bigger competitors who have more scale means they are up against an impossible task in my view. They can’t be the most functional or efficient provider because the r&d spend of their competitors is many multiples of ime’s revenue.

Cybically, i think they are signing up a hicksville mobile ultrasound company in aus and applying for fda to help their share price to help them raise capital.

so that brings us back to South America. I think ime has a chance of doing very well if their product is reasonable (which I highly doubt given that they were touting ‘new cross referencing ability’ 12 months ago, which is a feature that the better provider have been providing for more then a decade).
If they can keep signing up hospitals in South America and the developing world while the big competitors concentrate on the growing developed world, then they will do well. But the second a better competitor comes along, due to scalability of the software which is increasing by the year, I believe ime will be cactus, and I don’t think carestream/pme/intelerad will need to bother buying ime.

Having said that there is every chance ime 5bags prior, but I just don’t think they have a long term business, and buying this hoping a competitor buys them is rarely a strategy for success.

Expand

Justaguy In a teleconference a few months back IME's management explained that getting FDA approval and having soft launches in the USA and Oz was more about assisting with making it easier to win contracts in South America. They realised their resources were not sufficient to really tackle the USA and Oz. Maybe those plans have changed since, hence the CR.......though I hope not. Look back through some posts and questions raised by Composer and the replies, as a few were on the teleconference were this was discussed.

IME Price at posting: 4.1¢ Sentiment: None Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

What's causing the cost-of-living crisis, and how to navigate it

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint